Physician profile
Nathan E March
NPI 1467462762
$1,836.48
in general payments reported to CMS, 2019-2025
27 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.47 · 2020: $154 · 2021: $263 · 2022: $502 · 2023: $342 · 2024: $322 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $330.36 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $254.87 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $218.12 | 2022-2025 | |
| Astellas Pharma US INC | $172.14 | 2021-2024 | Veozah |
| Amgen INC. | $116.31 | 2021-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $98.63 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $65.76 | 2022-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $63.61 | 2019-2023 | |
| Lilly USA, LLC | $57.20 | 2021-2025 | Zepbound, Mounjaro, Emgality |
| E.R. Squibb & Sons, L.L.C. | $54.47 | 2020-2025 | Eliquis |
| Astrazeneca Pharmaceuticals Lp | $48.49 | 2020-2025 | Nexium, Farxiga |
| Sumitomo Pharma America, INC. | $42.18 | 2024 | Gemtesa |
| Alphatec Spine, INC | $38.46 | 2022 | |
| Horizon Therapeutics Plc | $24.44 | 2021-2022 | |
| Boston Scientific Corporation | $24.41 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $22.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.53 | 2020 | |
| Seqirus USA INC | $19.81 | 2022 | |
| Amarin Pharma, INC. | $19.28 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.17 | 2024 | Rexulti |
| Lundbeck LLC | $18.72 | 2025 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.50 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.70 | 2022 | |
| Philips North America LLC | $17.58 | 2023 | |
| Corium, LLC | $15.70 | 2023 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $14.84 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan March listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.